Haleos Labs Limited has approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a term of five years effective September 2, 2026, ensuring continuity in its leadership structure. The Board of Directors approved the proposal at its meeting held on May 29, 2026, based on the recommendations of the Audit Committee and Nomination & Remuneration Committee. The reappointment is subject to the approval of the shareholders of the Company.

Mrs. Sudeepthi Gopineedi’s current tenure as Whole-time Director concludes on September 1, 2026. The new term will commence on September 2, 2026, for a period of five consecutive years, although she will remain liable to retire by rotation. The Company affirmed that she is not debarred from holding the office of Director by any SEBI order or other regulatory authorities, in compliance with circulars issued by the National Stock Exchange of India Limited and BSE Limited dated June 20, 2018.

Mrs. Sudeepthi Gopineedi is a postgraduate from Birla Institute of Technology and Science, Pilani, with qualifications in Chemistry and Computer Science. Prior to joining Haleos Labs, she gained international experience working with multinational organisations such as Amazon, Oracle, The World Bank, and Blue Cross Blue Shield Association. During her tenure with the Company, she has led key quality and operational initiatives, including the successful completion of regulatory and customer audits.

The filing discloses her familial relationships within the Company's management. She is related to Mr. TVVSN Murthy, the Managing Director, as her father, and Mr. Talluri Venkata Praveen, the Executive Director, as her brother.

Mrs. Sundaramma Patibandla has resigned from the position of Independent Director at Haleos Labs Limited effective from the close of business hours on May 29, 2026. The resignation was tendered due to preoccupation and other professional commitments, as confirmed in a regulatory filing. Consequently, she has ceased to be a member of the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee of the company.

The Board of Directors discussed and accepted the resignation, placing on record its appreciation for her contributions during her brief tenure. The company confirmed that there are no other material reasons for her resignation beyond those stated in her resignation letter. Additionally, it was disclosed that she does not hold directorships or memberships on board committees of any other listed entities.

Haleos Labs Limited stated that despite this departure, the composition of the Board continues to remain duly constituted. The board maintains an optimum combination of Executive and Independent Directors, ensuring compliance with the requirements of Regulation 17 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The following table details the specifics of the disclosure regarding the change in directorship: